Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Buske

Showing results (101-110 of 148) with videos related to

Pageof 15
Sort By:
Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.
The New England Journal of Medicine|June 2, 2018
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's MacroglobulinemiaMeletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's MacroglobulinemiaEric Durot, Jithma P Abeykoon, Damien Roos-Weil, et al.
Blood|December 8, 2018
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J Castillo, Gilad Itchaki, Jonas Paludo, et al.
Blood|July 20, 2016
Treatment recommendations from the Eighth International Workshop on Waldenström's MacroglobulinemiaVéronique Leblond, Efstathios Kastritis, Ranjana Advani, et al.
Blood Advances|December 3, 2024
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemiaBenjamin M Heyman, Stephen S Opat, Björn E Wahlin, et al.
Blood|March 13, 2009
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)Friederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Hemasphere|June 5, 2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, et al.
The Lancet. Haematology|October 22, 2020
Consensus treatment recommendations from the tenth International Workshop for Waldenström MacroglobulinaemiaJorge J Castillo, Ranjana H Advani, Andrew R Branagan, et al.
Blood|March 1, 2012
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotypeFriederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Pageof 15

Showing results (101-110 of 148) with videos related to

Sort By:
Pageof 15
Future Oncology (London, England)|July 29, 2024
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialAlessandra Tedeschi, Constantine S Tam, Roger G Owen, et al.
The New England Journal of Medicine|June 2, 2018
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's MacroglobulinemiaMeletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's MacroglobulinemiaEric Durot, Jithma P Abeykoon, Damien Roos-Weil, et al.
Blood|December 8, 2018
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J Castillo, Gilad Itchaki, Jonas Paludo, et al.
Blood|July 20, 2016
Treatment recommendations from the Eighth International Workshop on Waldenström's MacroglobulinemiaVéronique Leblond, Efstathios Kastritis, Ranjana Advani, et al.
Blood Advances|December 3, 2024
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemiaBenjamin M Heyman, Stephen S Opat, Björn E Wahlin, et al.
Blood|March 13, 2009
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)Friederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Hemasphere|June 5, 2024
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAndreas J M Ferreri, Gerald Illerhaus, Jeanette K Doorduijn, et al.
The Lancet. Haematology|October 22, 2020
Consensus treatment recommendations from the tenth International Workshop for Waldenström MacroglobulinaemiaJorge J Castillo, Ranjana H Advani, Andrew R Branagan, et al.
Blood|March 1, 2012
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotypeFriederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Pageof 15